News
Prescient Therapeutics
Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of a range of cancers in Australia. The last earnings update…
News
Prescient Therapeutics starts Phase 1b clinical trial of its unique inhibitor PTX-100
On 11 July 2019, Prescient Therapeutics Limited (ASX: PTX) announced the commencement of a Phase 1b trial of its second targeted anti-cancer drug PTX-100 in patients with multiple…
News
Prescient Therapeutics Initiates Phase 1b Clinical Trial for First-in Class Anti-Cancer Drug PTX-100 in Patients with Multiple Cancers
Highlights: Innovative ‘basket’ study design will assess drug in multiple cancers Precision medicine approach offers a potentially faster development route International cancer expert Prof Miles…
News
Prescient Therapeutics’ drug candidates addressing the mutations causing cancer
Clinical-Stage oncology company, Prescient Therapeutics Limited (ASX: PTX) bases the foundation of its business model on the ground-breaking technology that addresses the mutations causing cancer. The company’s mainstream…
